Literature DB >> 168091

Central and peripheral contribution to the antihypertensive action of indoramin.

T Baum, A T Shropshire.   

Abstract

Indoramin has been reported to reduce blood pressure in experimental animals and humans. The complex pharmacological profile of the compound suggests that it may also exert central actions. Effects on spontaneous sympathetic outflow and on sympathetic nerve and blood pressure responses to hypothalamic stimulation were examined in anesthetized cats in the present study. At a low dose (1 mg/kg) indoramin reduced blood pressure but did not significantly influence the level of efferent sympathetic nerve activity. A higher dose (5 mg/kg) lowered pressure further and inhibited activity in the splanchnic, cardiac and renal nerves indicating that reduced sympathetic outflow is a contributing factor to the hypotensive response at this dose. However, in contrast to other centrally acting antihypertensive agents, e.g., clonidine, indoramin did not inhibit the increase in sympathetic nerve activity produced by hypothalamic stimulation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 168091     DOI: 10.1016/0014-2999(75)90319-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Hemodynamic responses to different levels of alpha-adrenergic interruption in congestive heart failure.

Authors:  A P Good; D V Unverferth; C V Leier
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

2.  Cardiovascular effects of indoramin in man--a dose ranging study.

Authors:  D P Nicholls; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

3.  Proceedings of the joint meeting of the Scandinavian and British Pharmacological Societies. Stockholm--Sweden. 5th and 6th July, 1982.

Authors: 
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

Review 4.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

5.  Differential blockade of alpha-adrenoceptors by indoramin.

Authors:  D P Nicholls; P C O'Connor; D W Harron; W J Leahey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

6.  Investigation into the cardioregulatory properties of the alpha 1-adrenoceptor blocker indoramin.

Authors:  V Pierce; N B Shepperson; M H Todd; J F Waterfall
Journal:  Br J Pharmacol       Date:  1986-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.